BiotechTube
i3 Pharmaceuticals

i3 Pharmaceuticals

Cambridge, United States· Est.
i3pharmaceuticals.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

i3 Pharmaceuticals is a specialty generic drug company founded by industry veterans to address high-barrier, complex solid oral dosage forms. The company's strategy centers on applying deep technical know-how to develop and manufacture generics for poorly soluble, unstable, or potent compounds, with a fully integrated US-based facility for development through commercial supply. Since its operational launch, i3 has successfully passed FDA inspections and commercialized several products, positioning itself in the niche but valuable market for technically challenging generics.

Infectious DiseaseCardiologyCentral Nervous SystemOther Specialty

Technology Platform

Integrated formulation and manufacturing expertise for complex solid oral generics, including sustained-release, bioavailability enhancement, and handling of poorly soluble/unstable/potent compounds.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The growing demand for affordable alternatives to high-cost, off-patent specialty drugs creates a large addressable market for complex generics.
i3's US-based manufacturing is a strategic asset, aligning with industry and government priorities for domestic supply chain resilience.
Their proven ability to develop and launch technically challenging products allows them to compete in less crowded, higher-margin niches of the generic market.

Risk Factors

The company faces intense competition and pricing pressure in the generic drug market, even for complex products.
Regulatory risks are significant, as any failure in development or during FDA inspections can halt product launches.
Dependence on a single manufacturing site creates operational concentration risk, where a disruption could impact the entire business.

Competitive Landscape

i3 competes with other specialty generic pharmaceutical companies such as Hikma, Lupin, and Amneal, as well as the complex generics divisions of larger players like Teva and Viatris. Its key differentiators are its focused expertise on high-barrier oral solids, fully integrated US operations, and a leadership team with a proven track record in product development and commercialization in this niche.

More companies in Drug Delivery & Formulation →More companies in United States →